Table 2.
Treatment duration of the sVRD regimen
| All patients (n = 16) | |
|---|---|
| Completion of 6 courses [n (%)] | 16 (100) |
| Mean treatment duration [courses (range)] | 8.0 (6–28) |
| Reason for discontinuation [n (%)] | |
| Completion of 6 courses | 7 (43.8) |
| Disease progression | 3 (18.8) |
| Second primary malignancy (acute lymphoblastic leukemia) | 1 (6.3) |
| Adverse events (pneumonia) | 1 (6.3) |
| Others | 4 (25.0) |